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Summary 
Cardiac fibroblasts (CF) are key players in the myocardial remodeling process and respond to 
myocardial damage or dysfunction by adopting a myofibroblast phenotype and undergoing 
increased proliferation, migration, secretion of bioactive molecules and turnover of the 
extracellular matrix. Many of the key cellular responses of the heart to injury or stress are 
mediated via specific signaling cascades involving the stress-activated protein kinases 
(SAPKs). The SAPKs comprise the p38 MAPK and c-Jun N-terminal kinase (JNK) families, 
both of which have been implicated in promoting myocardial damage and adverse cardiac 
remodeling. This review focuses on SAPK signaling cascades in the heart, with particular 
emphasis on their modulatory effects on CF function, inflammation and fibrosis. It also 
describes current and future therapeutic strategies for inhibiting SAPKs in the myocardium. 
Understanding the role of SAPK signaling at the cellular level holds potential for developing 
novel therapies to ameliorate cardiac dysfunction in man.   
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Introduction 
Adverse structural remodeling of the myocardium is the major contributor to morbidity and 
mortality associated with multiple cardiovascular diseases including hypertension, 
myocardial infarction, cardiomyopathy and heart failure. Both the major resident cell types of 
the heart, namely cardiomyocytes and cardiac fibroblasts (CF), play important yet divergent 
roles in the myocardial remodeling process. Cardiomyocytes are responsible for providing the 
contractile force of the heart and undergo hypertrophy in an attempt to compensate for 
cardiac dysfunction. In contrast, CF undergo cell proliferation and remodel the extracellular 
matrix (ECM) by altering the balance of ECM synthesis and degradation, in order to facilitate 
adaptation to altered myocardial function. Many such responses of myocytes and fibroblasts 
in the heart are regulated by the mitogen-activated protein kinase (MAPK) intracellular 
signaling cascades. In particular the stress-activated protein kinases (SAPKs), comprising the 
p38 MAPK and c-Jun N-terminal kinase (JNK) families, are activated by the ischemic and 
inflammatory stresses associated with myocardial injury and have been implicated in 
promoting myocardial damage and remodeling. 
 This review describes the key roles played by the p38 MAPK and JNK families in the 
heart, with particular emphasis on their modulatory effects on CF function with respect to 
fibrosis and inflammation. By identifying and understanding the function of myocardial 
SAPK pathways in a cell type-specific context, it is hoped that therapeutic strategies can be 
designed to reduce adverse myocardial remodeling and improve clinical outcomes in man.  
 
Myocardial Fibrosis and Inflammation 
Cardiac fibrosis, the disproportionate deposition of collagen-based ECM within the cardiac 
interstitium, is a common feature of ischaemic, dilated and hypertrophic cardiomyopathies 
and results in increased myocardial stiffness, ventricular dysfunction and arrhythmia, 
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ultimately leading to heart failure [1,2]. Cardiac fibrosis can be broadly classified as 
‘reparative’ or ‘reactive’ depending on the initiating stimulus and the pattern of collagen 
deposition [1,2]. 
 Reparative fibrosis describes the response of the heart to acute injury, for example 
scar formation after myocardial infarction (MI). Post-MI remodeling is characterized by a 
number of distinct phases including cardiomyocyte injury and death, acute inflammatory 
response, formation of granulation tissue, degradation of ECM, neovascularization, 
deposition of new ECM to form a scar, and ultimately resolution of the inflammatory 
response [3,4]. Pro-inflammatory and profibrotic cytokines and chemokines play integral 
roles in orchestrating reparative fibrosis of the infarcted myocardium by temporally altering 
the balance between ECM deposition (e.g. type I and III collagen synthesis) and degradation 
(increased matrix metalloproteinase (MMP) activity and/or decreased activity of their native 
inhibitors, TIMPs) [5].  
 Reactive fibrosis involves chronic deposition of collagen-based ECM in the absence 
of acute injury, for example in response to hypertension-induced pressure overload or in non-
infarcted regions of the post-MI heart. Reactive fibrosis represents an adaptive compensatory 
response aimed to increase the contractile force of the heart and is mediated by elevated 
levels of profibrotic hormones and growth factors and activation of mechanosensitive 
receptors [6,7]. Together, these changes alter the balance of ECM turnover in favor of 
collagen deposition. 
 Dissecting the cellular and molecular mechanisms underlying cardiac fibrosis and 
inflammation is imperative for designing therapeutic strategies for prevention and treatment 
of pathologies associated with adverse myocardial remodeling. Fibroblasts are the major 
producers of ECM proteins in the heart and CF are highly responsive to proinflammatory 
stimuli. As such, the CF represents an important cellular target for anti-fibrotic strategies.  
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Cardiac Fibroblasts 
Whilst cardiomyocytes occupy most of the cellular volume of the heart, the smaller CF are 
actually the most prevalent resident cell type in the adult human and rat heart, accounting for 
up to two-thirds of total cells [8,9]. Other non-myocyte cells permanently resident in the 
myocardium include vascular endothelial and smooth muscle cells, neuronal cells, mast cells 
and progenitor cells, which together account for an estimated 10% of resident cardiac cells 
[8,9]. Interestingly, a FACS-based analysis of the relative proportion of different cell types 
within adult murine heart revealed that CF are less prevalent (one-quarter of total cells) than 
in rat heart [9]. Irrespective of the absolute proportion of fibroblasts in the heart, this cell type 
has historically been under-represented in the scientific literature in comparison to 
cardiomyocytes. Although widely recognized as regulating turnover of ECM, it is becoming 
increasingly apparent that CF also have wide-reaching functions that are fundamental to the 
overall development, physiology and pathophysiology of the heart [10-13]. CF are in close 
contact with myocytes and vascular cells within the myocardium and may regulate cardiac 
electrophysiology through heterotypic cell-cell coupling via gap junctions [14,15]. CF also 
secrete a wide range of bioactive molecules including growth factors, cytokines and 
vasoactive peptides that can modulate local myocardial cell function through 
autocrine/paracrine actions [10]. Following damage to the heart (e.g. after MI or with 
pressure overload), CF undergo a series of functional changes that drive structural 
remodeling of the myocardium (see Box 1) [10]. These events initially serve to compensate 
for lack of cardiac function, but ultimately may lead to fibrosis and development of heart 
failure. In response to altered mechanical strain or specific humoral factors such as 
transforming growth factor- (TGF-) or angiotensin II (Ang II), CF undergo phenotypic 
modulation to become myofibroblasts, differentiated cells that exhibit increased migratory, 
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proliferative and secretory properties, and express contractile proteins such as -smooth 
muscle actin (SMA) [12]. Recent evidence suggests that in addition to derivation from 
resident CF, a proportion of myofibroblasts in the remodeling heart originate from 
hematopoietic bone marrow-derived fibrocytes, monocytes or endothelial cells [10-13]. In 
response to proinflammatory cytokines such as interleukin (IL)-1, tumor necrosis factor  
(TNF) and IL-6, myofibroblasts undergo increased proliferation and migration, and actively 
remodel the cardiac interstitium by increasing secretion of MMPs, increasing collagen 
turnover and secreting an array of growth factors and cytokines [10] (Box 1). The 
multifactorial role of CF in the myocardial remodeling process therefore makes them an 
attractive therapeutic target, distinct from the cardiomyocyte. 
 
Mitogen-Activated Protein Kinase (MAPK) Signaling Pathways 
MAPK signaling pathways are highly conserved three-tier phosphorylation/activation 
cascades that play fundamental roles in regulating every aspect of cell behavior from 
development, growth, survival, metabolism and movement to cell death. There are four 
classical MAPK signaling cascades, incorporating extracellular signal-regulated kinases 
(ERK1/2), p38 MAPKs, JNKs and ERK5 [16-18]. Additional atypical MAPKs (ERK3/4, 
ERK7, NLK) have also been identified [19], but these have not been well studied in the heart 
and will not be reviewed here. The canonical MAPK signaling cascade (Fig. 1) involves a 
series of specific phosphorylation events in which a MAP kinase kinase kinase (MAPKKK) 
phosphorylates and activates a MAP kinase kinase (MAPKK), which in turn phosphorylates 
and activates a MAPK. The dual phosphorylation of MAPK occurs on specific threonine and 
tyrosine residues within a conserved Thr-X-Tyr (TXY) motif, where X is Glu (ERK-1/2, 
ERK5), Gly (p38) or Pro (JNK). MAPK pathways exhibit a high degree of specificity, but 
also display crosstalk, synergism and redundancy [16-18]. Together, these signaling cascades 
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operate across species to regulate numerous aspects of cellular function through 
phosphorylation of a plethora of downstream substrates situated within the nucleus, cytosol, 
cytoskeleton, mitochondria and plasma membrane of the cell (Fig. 1). 
 The ERK-1/2 (p44/42-MAPK) pathway is activated predominantly by mitogenic 
stimuli (e.g. growth factors and G-protein coupled receptor ligands), and to a lesser degree by 
stress stimuli (e.g. proinflammatory cytokines), and is important for promoting cell 
proliferation, motility, differentiation and survival. The p38 and JNK pathways are activated 
primarily by environmental stresses and inflammatory cytokines, and as such are collectively 
known as stress-activated protein kinases (SAPKs). SAPKs can also be activated by 
mitogenic stimuli, albeit to a smaller extent. SAPK activation is often coupled to apoptotic 
and inflammatory responses. The more recently described ERK5, also known as big MAPK 
(BMK), is activated by both growth and stress stimuli and is generally coupled to increased 
proliferation and cell survival. The roles of ERK1/2 and ERK5 will not be discussed further, 
but the reader is referred to some excellent recent reviews on the roles of these MAPKs in the 
heart [16-18]. 
  
Stress-Activated Protein Kinases (SAPKs) 
p38 MAPK 
The p38 MAPK pathway is activated primarily by physical and chemical stresses and 
proinflammatory cytokines [16,17,20]. There are four known subtypes of p38 MAPK; p38 
(also termed SAPK2a/MAPK14), p38 (SAPK2b/p38-2/MAPK11), and the more distantly 
related p38 (SAPK3/ MAPK12/ERK6) and p38 (SAPK4/MAPK13); each of which is 
encoded by a separate gene. Several alternatively spliced forms of p38 have been described 
(e.g. CSBP1, Mxi2, Exip) and p38 also exists as two splice variants (p38 and p382). 
P38 and  share high sequence homology and can be inhibited by pyridinyl imidazole 
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compounds (e.g. SB203580), whereas the  and  subtypes are less homologous and resistant 
to inhibition by SB203580 and other similar inhibitors [21]. Although p38 appears to be 
ubiquitously expressed, expression of p38,  and  is restricted to particular tissues and cell 
types [22,23]. The canonical p38 MAPK signaling pathway (Fig. 2) involves phosphorylation 
of p38 on threonine and tyrosine residues in the TGY activation motif by the dual-specificity 
kinases MKK3 and MKK6 (and possibly MKK4). These MAPKKs are activated by upstream 
MAPKKKs including MEKKs 1-4, MLK3, TAK1 and ASK1. The downstream substrates of 
the p38 family include transcription factors (e.g. ATF2, ELK1, CREB, MEF2, p53 etc) as 
well as additional kinases such as MAPK-activated protein kinases (MAPKAPK2/3), MAP 
kinase interacting kinases (MNK1/2) and mitogen and stress-activated protein kinases 
(MSK1/2) [16,17,20].  
 Although the four p38 MAPK subtypes possess structural homology at the protein 
level and share a number of upstream activators and downstream substrates, several 
differences in their regulation and functional coupling are apparent. For example, MKK3 and 
MKK6 can differentially activate individual p38 subtypes depending on the initiating 
stimulus [24,25]. Furthermore, non-canonical activation of p38 can be induced through a 
unique mechanism involving the TAB1 scaffold protein which promotes autophosphorylation 
of p38, but not the other p38 subtypes [26]. These levels of specificity are likely due to 
subtle differences in protein structure, and may be influenced by binding of p38 subtypes and 
MKKs to scaffolding proteins of the JNK-interacting protein (JIP) family (e.g. JIP-2, JIP-4, 
OSM) [27]. However, the role of JIPs is less well defined for p38 than it is for JNK (see 
below). The duration and amplitude of p38 signaling is regulated by negative feedback 
involving dephosphorylation of the conserved Thr and Tyr residues by serine/threonine 
phosphatases (e.g. PP2A, PP2C), tyrosine phosphatases (e.g. HePTP, STEP) and dual-
specificity phosphatases (e.g. MKPs 1, 2, 4, 5, 7) [16,28].  
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JNK 
Members of the JNK family of SAPKs are activated primarily by stress stimuli and 
proinflammatory cytokines [16,17,29,30] (Fig. 3). JNKs are so-called because one of their 
earliest described actions was that of phosphorylating the N-terminal transactivation domain 
of c-Jun, a component of the AP-1 transcription factor. JNKs have subsequently been found 
to phosphorylate several additional transcription factors including JunD, ATF2, ELK1, p53, 
SMAD4, NFAT4 and HSF1 [17]. There are at least 10 human JNK isoforms derived from 
differential splicing of 3 genes (Jnk1, Jnk2 and Jnk3). JNK1 (SAPK/1c) and JNK2 
(SAPK/1a) are ubiquitously expressed, whereas JNK3 (SAPK/1b) expression is localized 
mainly to the central nervous system. All three JNKs exist as both short (46-48 kDa) and long 
(54-57 kDa) forms with distinct C-termini due to differential splicing [31]. JNKs are 
activated by dual phosphorylation in the TPY activation motif by the upstream dual-
specificity kinases MKK4 and MKK7, which themselves are activated by several MAPKKKs 
including MEKKs, MLKs, ASK1 and TAK1 (Fig. 3). JNKs are dephosphorylated and 
inactivated by a range of protein phosphatases including serine/threonine and tyrosine 
phosphatases, as well as the dual-specificity phosphatases MKP-1, 2, 5 and 7 [28]. The 
sequential components of the JNK pathway are physically associated through binding to 
particular scaffolding proteins (e.g. JIPs 1-4) that confer signal specificity and 
compartmentalization [27] (Fig. 3). Nuclear translocation of JNK enables transcription factor 
phosphorylation and altered expression of an array of genes, several of which play key roles 
in apoptosis [29]. In addition to these genomic effects, JNKs are also important for inducing 
cell death by inhibiting anti-apoptotic proteins (e.g. Bcl-2), stimulating pro-apoptotic proteins 
(e.g. Bad, Bim) and promoting mitochondrial cytochrome c release [29].  
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SAPK Signaling in the Heart 
SAPK signaling pathways play important roles in regulating many aspects of cardiac 
function. In addition to roles in normal physiology and development, SAPK pathways are 
activated in response to a range of stimuli associated with myocardial dysfunction including 
oxidative stress, inflammatory cytokines and altered mechanical force [16,18,32]. The vast 
majority of stimuli that activate the p38 pathway in the heart also activate the JNK pathway, 
albeit with differences in the magnitude and time course of activation. However, there is also 
limited evidence of differential activation of the p38 and JNK pathways in response to the 
same stimulus in myocardial tissue and cells. A particularly good example is the signaling 
response to myocardial ischemia. In perfused rat heart, ischemia activates p38 MAPK but 
does not activate JNK; subsequent reperfusion activates both p38 and JNK pathways [33]. 
Similarly, exposure of cultured cardiac myocytes or myoblasts to simulated ischemia in vitro 
activates the p38 pathway without stimulating the JNK pathway, whereas reperfusion 
activates both pathways [34,35]. Interestingly, reoxygenation-induced activation of the JNK 
pathway in hypoxic cardiomyocytes in vitro was not observed in parallel cultures of 
reoxygenated CF [36], suggesting cell-type specific signaling occurs in response to 
ischemia/reperfusion injury in the heart. Indeed, cell-specific ERK and p38 MAPK signaling 
has been observed in vivo following experimental myocardial infarction [37].  
 The roles of individual p38 subtypes (, , , ) and JNK isoforms (JNK1, 2, 3) in 
translating stress signals into changes in cardiac function are discussed below.  
 
p38 MAPK subtypes 
The most highly expressed p38 MAPK subtype in the adult human heart is p38, with lower 
levels of p38 and p38, and no detectable p38 mRNA or protein [38]. Similarly, adult 
mouse and rat hearts express mostly p38, with p38 protein expression occurring at low or 
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undetectable levels [39-44]. P38 protein has been detected in adult cardiac tissue from a 
number of species [22,38,45], but p38 has relatively low expression in the heart [38,45]. 
 
p38 
P38 (often referred to simply as p38) is by far the most well studied isoform and has been 
investigated in the heart using a range of approaches. In contrast to the other p38 subtypes, 
p38 knockout mice die in utero due to placental abnormalities [46]. Therefore in vivo 
studies on myocardial p38 function have relied on pharmacological p38 inhibitors [21], 
p38+/- heterozygous animals [40], dominant negative (DN) p38 mutants [47] or modulation 
of upstream/downstream components of the p38 signaling pathway [47]. More recently, 
application of conditional Cre-lox technology to delete the p38 gene in particular cell types 
has overcome the lethality of the systemic knockout and provided a useful tool for 
investigating the function of p38 at the level of the cardiomyocyte in in vivo murine models 
[43,48]. 
 Since the role of p38 in the heart has been extensively reviewed in recent years 
[16,18,49-51], only a summary will be provided here. Much of the evidence for the 
importance of p38 has been acquired through the use of pharmacological inhibitors of 
p38/ (e.g. SB203580). P38 is generally viewed as a critical mediator of cardiac 
dysfunction, making it an attractive target for therapeutic intervention [21,50,52]. P38 
exacerbates ischemia/reperfusion injury and promotes cardiomyocyte apoptosis, myofilament 
modulation, proinflammatory gene induction and ECM remodeling, all of which can 
contribute to adverse myocardial remodeling and development of heart failure [16,18,49-51]. 
Conversely, p38 activation underlies some of the protective effects conferred by ischemic 
preconditioning [53]. Nevertheless, strategies aimed at inhibiting p38 in the heart are being 
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developed as therapies for treating cardiac dysfunction [50,52].   
 
p38 
Despite being expressed at relatively low levels in the myocardium, p38 is purported to 
have important functional effects in the heart. However, it should be noted that most of the 
evidence for this has been compiled from approaches involving ectopic expression of wild-
type or mutant p38 in cultured neonatal cardiomyocytes, rather than studying the 
endogenous protein. Several such studies have indicated that p38 and p38 have opposing 
roles in cardiomyocytes. For example, simulated ischemia activates p38, but reduces p38 
activity [54], and while overexpression of p38 promotes apoptosis of cardiomyocytes, p38 
overexpression increases myocyte hypertrophy and survival [55,56]. In transgenic mice with 
systemic overexpression of DN-p38 or DN-p38, pressure overload-induced hypertrophy 
was similar to that in wild type animals, but mutant mice exhibited reduced cardiac fibrosis 
[57]. An elegant chemical-genetic study using p38 knockout mice and mice expressing 
SB203580-resistant forms of p38 and p38 recently determined that p38 rather than p38 
was important for ischemic preconditioning [53]. Thus, there remains scant information on 
the role of endogenous p38 in the heart and given its low expression in the myocardium the 
importance of this subtype remains questionable.  
 
p38 and p38  
P38 (SAPK3) is expressed in human, mouse, rat, dog and pig heart [22,38], and its mRNA 
and protein levels in mouse heart are similar to those of p38 [45]. In contrast to the 
cytoplasmic and nuclear localization of p38 and p38, p38 was found to be localized 
exclusively in the cytoplasm in cultured neonatal rat cardiomyocytes [22]. However, nuclear 
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p38 has been observed in cardiomyocytes in vivo following pressure overload [45]. P38 
activity is increased in the infarcted and remote myocardium following experimental MI in 
mice [37]. However, despite the clear evidence of p38 expression and activation in the heart, 
its functional role in the myocardium remains undefined. Further studies with p38 knockout 
mice are clearly warranted to determine the precise role of this prevalent cardiac p38 subtype.  
 The role of p38 in the heart is less clear still. Analysis of p38 subtype expression in 
mouse heart revealed that p38 is lowly expressed at the mRNA and protein level (similar to 
p38) [45], although our own studies in human CF from multiple patients suggest somewhat 
higher expression than p38 [58]. We recently showed that the p38/// inhibitor BIRB-
0796 significantly reduced IL-1-induced MMP-1 and MMP-10 expression in human CF; 
effects not observed with the classical p38/ inhibitor SB203580 [59]. These data implicate 
p38 and/or p38 in modulating expression of MMP-1 and MMP-10 in these cells, although 
further studies are needed to confirm this.     
 
JNK subtypes 
Western blot analysis has identified JNK1 and JNK2 as the major subtypes expressed in 
mouse heart, with no apparent expression of JNK3 [60]. Although neonatal rat 
cardiomyocytes have been reported to express all three JNK subtypes [61], the evidence for 
JNK3 is unclear and may rather reflect splice variants of JNK1 and 2. 
 The role of the JNK family in cardiac remodeling has been studied in vivo and in vitro 
using both gain-of-function models (e.g. overexpression of constitutively active mutants of 
JNKs or their upstream activators) and loss-of function models (e.g. knockout of JNK 
isoforms, or overexpression of DN mutants of JNKs or their upstream activators). These 
investigations have implicated the various JNK isoforms, especially JNK1, in the induction of 
cardiac hypertrophy, myocyte cell death and myocardial remodeling [16]. However, the role 
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of JNK is complex and many studies have reported conflicting results [16]. Some of these 
discrepancies may be explained by the functional redundancy that is evident between JNK 
isoforms. For example, knockout mice deficient in either JNK1, JNK2 or JNK3 all developed 
pressure overload-induced hypertrophy similar to wild-type animals [62], whereas deletion of 
upstream activators of these JNK isoforms, MKK4 [63] or MKK7 [64], reduced cardiac 
hypertrophy due to inhibition of JNK signaling. Recent evidence also suggests that JNK1 can 
have a dual function, conferring both beneficial and detrimental effects depending on the 
metabolic state of the heart [65]. Thus, JNK1 is proposed to act as a conditional survival 
kinase that protects the heart against brief ischemic episodes, but not against prolonged 
ischemia.     
 
Therapeutic Targeting of SAPK Pathways in the Heart 
Evidence gathered from genetic manipulation of SAPKs indicates that the p38 and JNK 
pathways represent viable therapeutic targets for ameliorating myocardial dysfunction. 
Several pharmacological SAPK inhibitors, particularly those targeting p38 MAPK, have been 
evaluated in animal models of cardiovascular disease and in clinical trials (Table 1 and 2). 
 
p38 MAPK 
The most widely studied p38 inhibitors are the pyrindinyl imidazole compounds, such as the 
archetypal SB203580 and the structurally similar SB202190 (Table 1). This class of 
molecules inhibit p38 and p38 by binding to the active site in an ATP-competitive manner, 
but they do not inhibit the  or  subtypes due to fundamental differences in the protein 
sequence of the active site [21]. SB203580 and SB202190 are relatively specific for p38/, 
but can also effectively inhibit several other kinases including glycogen synthase kinase 
(GSK)-3, casein kinase 1 and cyclin G-associated kinase [66]. A number of second and 
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third generation p38/ inhibitors have been designed that are orally active, including 
SB239063, SB681323 (Dilmapimod), RWJ-67657, GW85655 (Losmapimod) and SCIO-469 
(Talmapimod) (Table 1). Several inhibitors that preferentially target p38 over p38 have 
also been developed including SD-282, VX-702 and RO4402257 (Pamapimod) (Table 1). 
None of the above inhibitors affect p38 or p38 activity. In contrast, the diaryl urea 
compound BIRB-0796 is structurally and functionally distinct from the other p38 inhibitors 
and can inhibit all four p38 subtypes in a non-competitive manner in vivo and in vitro, albeit 
with slight selectivity for the  and  subtypes [67]. BIRB-0796 does not inhibit any of the 
other kinases inhibited by pyrindinyl imidazoles, but it is a potent inhibitor of JNK2 (but not 
JNK1 or JNK3) [66].     
 There is good evidence that pharmacological inhibitors of p38 can improve contractile 
function, reduce ischemic injury and ameliorate fibrosis in animal models of cardiac 
dysfunction [16,21,50,52]. Given their potent anti-inflammatory effects, most clinical trials of 
p38 inhibitors to date have assessed their impact on inflammatory disorders such as 
rheumatoid arthritis and Crohn’s disease [68]. Early trials did not progress beyond phase 2 
due to adverse side effects. More recently, however, trials of lower doses of p38 inhibitors 
have been better tolerated, although they have failed to provide much benefit when compared 
with alternative anti-inflammatory drugs [68]. Nevertheless, a number of trials are underway 
to investigate the effects of p38 inhibition on cardiovascular disease and its complications, 
including angioplasty (VX-702, SB681323[69]), atherosclerosis (GW85655) and non-ST 
elevation MI (GW85655) [50].  
 
JNK 
In contrast to the diverse range of studies with p38 inhibitors, there are relatively few studies 
using pharmacological JNK inhibitors to modulate cardiac remodeling. The main JNK 
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inhibitors investigated to date are SP600125, AS601245 and XG-102 (Table 2), all of which 
are pan-specific i.e. inhibit JNK1, 2 and 3 with similar efficacies [30,70]. SP600125 was one 
of the first small molecule ATP-competitive JNK inhibitors to be developed and is the most 
widely studied. However, this compound is actually relatively non-selective for JNK, 
inhibiting at least 15 other kinases with similar or greater potency [66]. SP600125 had 
detrimental effects on myocardial remodeling in a hamster cardiomyopathy model, contrary 
to the effects of a p38 inhibitor [71]. However, SP600125 had beneficial effects on cardiac 
function and fibrosis in a recent study employing a murine model of cardiomyopathy [72]. 
AS601245 is an ATP-competitive small molecule JNK inhibitor that appears to be slightly 
more selective than SP600125 [66]. AS601245 reduced infarct size and cardiomyocyte cell 
death following ischemia-reperfusion injury in rats [73]. XG-102 (also known as D-JNKI-1) 
is a novel cell-permeable peptide based on the JNK-binding sequence of JIP-1 [74]. XG-102 
appears to be more selective than the non-peptide inhibitors, and has been shown to be 
protective against myocardial ischemia-reperfusion injury in rats [75]. Thus, there is limited 
pre-clinical evidence that JNK inhibitors may be beneficial in reducing adverse myocardial 
remodeling, but none of these molecules have yet undergone clinical evaluation. The 
development of a new generation of more selective JNK inhibitors [30] may make this goal 
achievable in the coming years.    
 
SAPK Roles in Cardiac Fibroblasts  
Animal models have proved important for determining the effects of inhibiting SAPK 
pathways on global myocardial remodeling. However, the complexity of the interrelationship 
between myocytes and fibroblasts and other cell types within the heart makes precise 
interpretation of pharmacological inhibitor experiments difficult, as effects on one cell type 
can manifest themselves in another cell type through direct cell-cell contact or 
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autocrine/paracrine signaling. Given the cell-specific nature of signaling pathways, it is not 
surprising (but often overlooked) that MAPK and SAPK signaling differs between myocytes 
and CF in vivo. For example, in a murine model of MI, p38 phosphorylation was increased in 
both myocytes and non-myocytes in the infarct and border zone and in the myocytes of the 
remote non-ischemic area [37]. In contrast, ERK phosphorylation was localized to non-
myocytes in areas of fibrosis in both infarct and remote regions of the myocardium. This 
heterogeneity of cellular signaling responses is rarely considered and may offer avenues for 
selective therapeutic modulation.   
 Components of SAPK pathways have been manipulated selectively in cardiomyocytes 
in vivo by exploiting the MHC promoter to drive cardiomyocyte-specific expression or 
deletion of specific proteins [63,64,76]. Such models are cardiomyocyte-specific, not 
“cardiac-specific” as they are sometimes misleadingly referred to in the literature; an 
important distinction when considering the role of the CF. In stark contrast to the situation 
with cardiomyocytes, SAPK-targeting strategies aimed specifically at the fibroblasts of the 
heart have not yet been reported. In vitro cell culture models have therefore proved 
invaluable in delineating the function of distinct SAPK signaling pathways in regulating CF 
function, as discussed below.  
 
p38 MAPK 
The role of p38 MAPK has been studied in vitro predominantly through the use of 
pharmacological inhibitors of p38/ (SB203580, SB202190, RWJ-67657) and p38/// 
(BIRB-0796), as well as through the use of molecular biological techniques such as 
overexpression of DN-p38 mutants. Such studies (summarized in Table 3) have provided 
evidence that p38 MAPK subtypes, particularly p38, are involved in regulating many of the 
key functions of CF in the myocardial remodeling process (Box 1). For example, p38 
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regulates expression of a range of proteins involved in inflammation, including cytokines and 
chemokines (IL-1, IL-1, IL-6, TNF, MCP-1, SDF-1, COX-2) [77-85] and intercellular 
adhesion molecules (ICAM-1 and VCAM-1) [86].  
 The evidence for p38 MAPK regulating IL-6 expression is particularly well 
documented and has been observed in CF of human, rat and mouse origin in response to 
numerous stimuli [77-82]. In human CF, we demonstrated that both TNF and IL-1 could 
stimulate the p38 MAPK pathway and induce IL-6 mRNA and protein secretion that was 
attenuated by SB203580 [77,78]. Ang II-induced IL-6 mRNA expression in neonatal rat CF 
was mediated via a p38-dependent mechanism culminating in activation of the CREB 
transcription factor and IL-6 gene transcription [79]. A similar p38- and CREB-dependent 
mechanism appears to underlie 2-adrenergic receptor-induced IL-6 expression in neonatal 
mouse CF [81]. In adult mouse CF, both an agonist of AMP kinase (AICAR) [82] and 
adenosine [80] could stimulate IL-6 secretion in a SB203580-sensitive manner, with the 
results of the latter study being confirmed by overexpression of DN-p38 [80]. Interestingly, a 
gene profiling study highlighted IL-6 as a central molecule upregulated in the adult rat heart 
following adenoviral gene transfer of constitutively active MKK3 and wild-type p38 [87]. 
This is likely to be important in the remodeling heart, as IL-6 stimulates left ventricular 
hypertrophy and fibrosis in the absence of an inflammatory response or effects on blood 
pressure [88].  
 The p38 pathway has been implicated in both degradation and synthesis of ECM 
components. For example, cytokine-induced expression of ECM-degrading MMPs 1, 3, 9 and 
10 occurs via p38-dependent pathways [59,89,90]. In human CF, we obtained evidence for a 
differential role of individual p38 subtypes in this context. While IL-1-induced MMP-3 was 
inhibited by either a p38/ inhibitor (SB203580) or a p38/// inhibitor (BIRB-0796), IL-
1-induced MMP-1 and MMP-10 expression was sensitive only to inhibition by BIRB-0796 
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[59]. As human CF express the ,  and  subtypes of p38 at the mRNA and protein level, but 
relatively little p38 (NA Turner, unpublished observations and [58]), this suggests roles for 
p38 in stimulating MMP-3 expression, and  for p38 or p38 in stimulating MMP-1 and 
MMP-10 expression. However, it should be noted that BIRB-0796 is also a potent inhibitor 
of JNK2 [66]. Conflicting reports exist for the role of the p38 pathway in mediating IL-1-
induced MMP-3 and MMP-9 expression in rat and human CF [59,90]. In adult rat CF, IL-1-
induced protein expression of MMP-3 was p38-independent and that of MMP-9 was p38-
dependent [90]. However, in adult human CF we reported that IL-1-induced MMP-3 mRNA 
expression was p38-dependent and MMP-9 mRNA expression was p38-independent [59], 
suggesting important  inter-species differences may exist.  
 ADAMTS1 (a disintegrin and metalloproteinase domain with thrombospondin motifs 
1) is a secreted protease that is a potent inhibitor of angiogenesis [91]. We determined that 
both SB203580 and BIRB-0796 inhibit ADAMTS1 mRNA expression in human CF in the 
absence or presence of IL-1 stimulation [59]. These data imply that p38 MAPK inhibition 
could promote neovascularization in vivo.      
 Profibrotic effects of the p38 pathway in CF have also been reported. For example, 
p38 inhibition with SB203580 or RWJ-67657 reduced type I collagen gene expression in rat 
CF [92-94]. Moreover, oncostatin M-induced expression of TIMP-1 (a negative regulator of 
MMP activity) was sensitive to p38 inhibition in human CF [95]. Additionally, mechanical 
stretch induced angiotensinogen gene expression in neonatal rat CF via RhoA-induced 
activation of p38 [96,97], likely contributing to Ang II-mediated pro-fibrotic changes in the 
heart. The involvement of p38 in both degradation and synthesis of ECM by CF makes the 
net effect of p38 inhibition on ECM remodeling complex. However, the majority view is that 
p38 inhibition reduces cardiac fibrosis in vivo [16,57,92,98]. Whether these effects are due to 
direct modulation of ECM turnover by CF rather than downstream consequences of improved 
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cardiomyocyte function is not clear. In support of the latter scenario, overexpression of DN-
p38 specifically in cardiomyocytes reduced fibrosis in a diabetic cardiomyopathy model 
without directly affecting p38 activity in CF [99]. 
 Besides effects on gene expression, p38 also regulates several cellular properties of 
CF that are important to the myocardial remodeling process. For example, TGF-induced 
differentiation of CF to myofibroblasts is inhibited by the p38/ inhibitor RWJ-67657 both 
in vivo and in vitro [92,100]. IL-1-induced migration of neonatal rat CF can be attenuated by 
p38 inhibition, although JNK and ERK appear to play more pronounced roles [101]. In a 
recent study, the adipokine visfatin was shown to increase DNA synthesis (a marker of cell 
proliferation) in rat CF via a p38-dependent, JNK-independent mechanism [94]. Finally, 
SB203580 protected neonatal rat CF against ischemia-induced cell death, suggesting that p38 
is important for mediating the detrimental effects of ischemia on these cells [102].  
 Taken together, the results of these in vitro studies on CF (Table 3) suggest that p38 
MAPK regulates production of inflammatory mediators, ECM turnover and cell proliferation, 
migration and myofibroblast differentiation, all of which are important in the myocardial 
remodeling process. As such, the p38 MAPK pathway in CF represents a potential 
therapeutic target for reducing adverse myocardial remodeling. 
 
JNK 
The role of the JNK pathway in CF is much less well studied than the p38 pathway. Almost 
all of our current knowledge on the role of JNK in CF has been acquired from the use of a 
single pharmacological JNK inhibitor, SP600125 (Table 4). As highlighted earlier, in 
addition to JNK this agent also inhibits at least 15 other kinases with similar or greater 
potency [66], and hence an element of caution must be applied when interpreting results 
obtained solely with this inhibitor. 
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 In rat CF, SP600125 reduced ET-1-induced SMA expression and collagen synthesis, 
both markers of myofibroblast differentiation [103]. SP600125 also inhibited CF migration 
induced by IL-1 family cytokines (IL-1 or IL-18) [101,104], and cell proliferation induced by 
the chemokine CXCL16 [105]. Additionally, SP600125 inhibited IL-1-induced protein 
expression of MMP-3 in adult rat CF [90]. Although MMP-9 expression was not sensitive to 
SP600125 in that study [90], another group reported that IL-1-induced MMP-9 expression 
was mediated by a pathway involving specific protein kinase C subtypes and JNK in adult rat 
CF [106]. Matricellular proteins are non-structural components of the ECM that regulate cell-
matrix interactions and cellular function [107]. The ability of CF to synthesize two such 
matricellular proteins (periostin and osteopontin) has also been shown to be inhibited by 
SP600125, and a role for JNK signaling downstream of ROS generation suggested [108,109]. 
Plasminogen activator inhibitor-1 (PAI-1), which is associated with increased risk of 
cardiovascular disease, can be secreted by both myocytes and fibroblasts in the heart [110]. 
Adenovirus-mediated gene transfer of DN kinase mutants in neonatal rat CF revealed that 
Ang II or ET-1-induced PAI-1 expression occurred via a JNK-dependent (p38-independent) 
mechanism [110].     
 The JNK pathway can also negatively regulate expression of some genes in CF. For 
example, SP600125 or overexpression of DN mutants of JNK1 or JNK2 significantly 
increased basal and mechanical stretch-induced angiotensinogen expression in neonatal rat 
CF; opposite to the effects of p38 MAPK inhibition [96,97]. Moreover, in our own studies 
using adult human CF, SP600125 increased basal and IL-1-induced IL-6 mRNA expression; 
again converse to the effects of p38 inhibition [77].   
 Taken together, the above studies suggest a role for JNK signaling pathways in 
regulation of CF proliferation, migration, differentiation and ECM regulation (Table 4). 
Although the evidence is not as strong as it is for p38 MAPK, the JNK pathway in CF may 
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also represent a viable therapeutic target for reducing adverse myocardial remodeling. 
 
Future Perspective 
The role of MAPK signaling pathways and their coupling to cellular function are clearly 
different in cardiomyocytes and non-myocytes and hence prevention of adverse myocardial 
remodeling may require cell type-specific manipulation of MAPK activation. As the 
importance of the CF is increasingly recognized, strategies for selectively targeting this cell 
type in the myocardium will begin to emerge. The three major approaches that offer potential 
in this respect are pharmacological, genetic and cell-based therapies [111]. 
 Pharmacological approaches can offer cell type-specificity depending on the target in 
question. Several classes of widely prescribed drugs for patients with cardiovascular disease 
(e.g. statins, beta-blockers, ACE inhibitors) have beneficial effects on myocardial remodeling 
that appear to be due in part to modulation of CF function [10]. With respect to SAPK 
signaling, in vitro studies have shown defined roles for SAPK pathways in modulating 
diverse cellular functions of import to the remodeling process. However, the net effect of 
pharmacological inhibition in vivo depends upon the role of SAPK pathways in all cell types 
and therefore is far more complex. One avenue that may be of value is in exploiting the 
differential isoform expression of specific JNKs and p38 MAPKs in different cell types. By 
understanding the cell-specific expression patterns of SAPK isoforms, it may be possible to 
design therapies targeted at particular isoforms which would then favor a particular cell type 
in the heart. The question remains as to whether global inhibition of all JNKs or p38 MAPKs 
is more beneficial than isoform-specific inhibitors. In the case of p38, most pharmacological 
studies to date have utilized /-selective inhibitors, but the potentially opposing roles of the 
 and  subtypes (e.g. in cardiomyocyte hypertrophy and apoptosis [55]) cannot be ignored. 
Moreover, inhibition of p38 or p38 in the heart has not been well explored, although agents 
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such as BIRB-0796 can inhibit these subtypes in addition to p38-/. Isoform-selective JNK 
inhibitors are also being developed [30,70].    
 Another aspect that deserves consideration is whether SAPK signaling differs in CF 
compared with fibroblasts from other organs. This is important because SAPK-targeting 
therapies that are ineffective in one clinical setting may be more effective in another. Cardiac 
fibroblasts arise from the primitive heart tube and are developmentally distinct from 
fibroblasts from other tissues [112]. A systematic review of in vitro studies on skin, lung, 
synovial, liver and heart fibroblasts highlighted several important differences in their 
response to proinflammatory cytokines [113]. It is also likely that diversity in SAPK 
signalling exists between different fibroblast populations as a result of differential SAPK 
subtype expression. For example, synovial fibroblasts in tissue from rheumatoid arthritis 
patients expressed p38 and p38, but did not express p38 even though this was observed in 
macrophages [114]. This is in marked contrast to human CF, in which p38 is the most 
abundant isoform [58]. 
In comparison to the cardiomyocyte, the CF has been relatively unexplored as a target 
for gene therapy. Whilst there has been much progress in studying the function of specific 
proteins in cardiomyocytes through use of MHC gene promoter-driven strategies, the lack 
of a CF-specific enhancer/promoter has clearly held back in vivo research at the level of the 
CF. Fibroblasts from other tissues (e.g. skin and lung) have been targeted using fibroblast-
specific enhancers (e.g. Col1a2 promoter [115]), but this technology has not yet been applied 
to the heart. Fibroblasts and cardiomyocytes have been differentially targeted in the 
myocardium using a specific promoter region of the mouse periostin (Postn) gene [116]. 
Periostin is a matricellular protein whose expression is restricted to the non-myocyte lineage 
of the neonatal heart and is not expressed by cardiomyocytes [117], although it is expressed 
in other connective tissues within the body. The GATA4 transcription factor is expressed by 
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cardiomyocytes and CF, but interestingly does not appear to be expressed by fibroblasts from 
other organs [118]. Whether elements within the GATA4 gene could be exploited to facilitate 
gene therapies aimed specifically at the CF has yet to be investigated. Thus, identification of 
a CF-specific promoter / transcriptional enhancer is an important goal if the full potential of 
selectively modulating CF function in vivo is to be realized [111]. This may then open up 
new avenues for assessing the role of SAPK pathways in CF and their role in myocardial 
remodeling.  
 Cell-based therapies involve the introduction of exogenous cells (e.g. cardiomyocytes, 
stem cells or fibroblasts) into the heart to ameliorate cardiac dysfunction. There is a small 
body of evidence that transplantation of wild-type or genetically-modified CF into the heart 
can offer therapeutic benefit in reducing adverse cardiac remodeling [111]. For example, 
injection of CF over-expressing the GATA4 transcription factor [119], erythropoietin [120] 
or VEGF [121] has been used to attempt to ameliorate myocardial remodeling in rat models 
of MI. Although the erythropoietin approach did not offer long-term benefit [120], the 
GATA4-expressing CF improved cardiac function and reduced adverse myocardial 
remodeling [119]. Moreover, transplantation of VEGF-expressing CF into infarcted areas of 
the heart one day after MI promoted neovascularization and attenuated cardiac dysfunction 
measured 4 weeks later [121]. This latter study offers particular therapeutic potential as the 
favorable effects of CF transplantation were apparent after induction of MI. By adopting a 
similar strategy for activating or inhibiting selective SAPK pathway components in 
exogenous CF, and then transplanting them into the heart, we may be able to gain a more 
detailed understanding of the role of SAPK signaling specifically in CF in vivo. 
 
Concluding Remarks 
In summary, SAPK signaling pathways play important roles in regulating cardiac 
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development and physiology, but are also key proponents of cardiac dysfunction. Whilst the 
p38 and JNK pathways have been well explored in cardiomyocytes, increasing evidence 
supports a role for SAPK signaling in many aspects of CF function that are central to the 
myocardial remodeling process. This knowledge provides an opportunity to design focused 
interventional therapies targeted specifically at CF. In this respect, pathway-specific targeting 
holds potential for modulating fibroblast functions that are perceived as detrimental, whilst 
sparing other favorable effects of this important myocardial cell type. 
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Figure Legends 
Fig.1. Canonical MAPK signaling cascades.  
MAP kinase kinase kinases (MAPKKKs) phosphorylate MAP kinase kinases (MAPKKs) on 
specific serine/threonine residues. This results in MAPKK activation and subsequent dual 
phosphorylation of MAPKs on specific threonine and tyrosine residues within the conserved 
Thr-X-Tyr  activation motif. MAPKs regulate multiple facets of cellular function by 
phosphorylating downstream substrates localized in the nucleus (e.g. transcription factors), 
cytosol, cytoskeleton, mitochondria and plasma membrane. Abbreviations: ASK: apoptosis 
signal regulating kinase; ERK: extracellular signal regulated kinase; JNK: c-Jun N-terminal 
kinase; MAPK: mitogen-activated protein kinase; MEK: MAPK/ERK kinase; MEKK: 
MAPK/ERK kinase kinase; MKK: MAP kinase kinase; MLK: mixed lineage kinase; TAK: 
transforming growth factor- activated kinase. 
 
Fig. 2. The p38 MAPK signaling pathway.  
Abbreviations: ASK: apoptosis signal regulating kinase; ATF: activating transcription 
factor; C/EBP: CCAAT/enhancer binding protein; CHOP: C/EBP-homologous protein; 
CREB: cyclic AMP response element binding protein; DLK: delta like homolog; ELK: Ets-
like gene; HBP: high-mobility group box protein; MAPK: mitogen-activated protein kinase; 
MAPKAPK: mitogen-activated protein kinase-activated protein kinase; MEF: myocyte 
enhancer factor; MEKK: MAPK/ERK kinase kinase; MKK: mitogen-activated protein kinase 
kinase; MAPKK: mitogen-activated protein kinase kinase; MAPKKK: mitogen-activated 
protein kinase kinase kinase; MLK: mixed lineage kinase; NFAT: nuclear factor of activated 
T-cells; NHE: Na+/H+ exchanger; MNK: mitogen-activated protein kinase interacting 
kinase; MSK: mitogen and stress-activated protein kinase; PLA2: phospholipase A2; PRAK: 
p38-regulated/activated protein kinase; SAP1: serum response factor accessory protein; 
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TAK: transforming growth factor- activated kinase; TAO: thousand and one amino acid 
protein kinase; TPL2: tumor  progression locus 2; USF: upstream transcription factor; ZAK: 
leucine zipper and sterile- motif kinase. 
 
Fig. 3. The JNK signaling pathway.  
Abbreviations: ASK: apoptosis signal regulating kinase; ATF: activating transcription 
factor; ELK: Ets-like gene; GR: glucocorticoid receptor; HSF: heat shock factor; IRS: 
insulin receptor substrate; JIP: JNK-interacting protein; JNK: c-Jun N-terminal kinase; 
MAP2/1B: microtubule associated protein 2 and 1B; MAPK: mitogen-activated protein 
kinase; MAPKK: mitogen-activated protein kinase kinase; MAPKKK: mitogen-activated 
protein kinase kinase kinase; MEKK: MAPK/ERK kinase kinase; MKK: mitogen-activated 
protein kinase kinase; MLK: mixed lineage kinase; NFAT: nuclear factor of activated T-
cells; PPAR: peroxisome proliferator-activated receptor; RXR: retinoid receptor; SMAD: 
SMA and MAD homolog; TAK: transforming growth factor- activated kinase.  
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Table 1. Properties of common p38 inhibitors
Inhibitor
Primary 
Target
Notes Chemical Structure
SB203580
SB202190
p38/
First generation 
inhibitors. 
Pyridinyl 
imadazole 
compounds. 
Also inhibit other 
kinases 
including GSK3 
and CK.
SB203580 SB202190
SB239063 p38/
Second 
generation 
pyridinyl 
imadazole 
inhibitor. Orally 
active.
BIRB-0796
(Doramapimod)
p38/ > 
p38/
Second 
generation diaryl
urea inhibitor. 
Orally active. 
Slightly selective 
for p38/ over 
/. Also potently 
inhibits JNK2.
SB681323
(Dilmapimod)
p38/ Orally active.
RWJ-67657 p38/
Potent. Orally 
active.
GW85655
(Losmapimod)
p38/ Orally active.
SCIO-469
(Talmapimod)
p38/
Orally active 
third generation 
inhibitor. 
SD-282 p38
Orally active. 
Selective for 
p38 over p38.
VX-702 p38
Orally active 
third generation 
inhibitor. Highly 
selective.
RO4402257 
(Pamapimod)
p38
Orally active 
third generation 
inhibitor. 
Selective for 
p38 over p38. 
Also inhibits 
JNK2 and JNK3.
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Table 3. Effect of p38 MAPK inhibition on cardiac fibroblast function in 
vitro 
Target Stimulus Inhibitor CF Source Reference 
Inflammation 
↑ IL-1, IL-1 TNF SB203580 Human [78] 
↑ IL-6 IL-1, TNF, Ang 
II, Adenosine, 
AMP kinase, 
-AR stimulation 
SB203580, 
DN-p38 
Human, 
Rat, 
Mouse 
[77-82] 
↑ TNF IL-1 SB203580 Human [77] 
↑ MCP-1 Ang II DN-p38 Rat [83] 
↑ SDF-1 Oncostatin M SB202190 Human [84] 
↑ COX-2 Ang II SB203580 Rat [85] 
↑ ICAM-1, 
VCAM-1 
IL-1 SB203580 Rat [86] 
ECM turnover 
↑ MMP-1 IL-1, IL-17 SB203580, 
BIRB-0796 
Human [59,89] 
↑ MMP-3 IL-1 SB203580, 
BIRB-0796 
Human [59] 
↑ MMP-9 IL-1 SB202190 Rat [90] 
↑ MMP-10  IL-1 BIRB-0796 Human [59] 
↑ TIMP-1 Oncostatin M SB202190 Human [95] 
↑ Type I collagen TGF-, AGEs, 
visfatin 
RWJ-67657, 
SB203580 
Rat [92-94] 
Cell function 
↑ Myofibroblast  TGF- RWJ-67657 Rat [92] 
↑ Cell 
proliferation 
Visfatin SB203580 Rat [94] 
↑ Cell migration IL-1 SB202190 Rat [101] 
↓ Cell survival Ischaemia SB203580 Rat [102] 
Other 
↑ 
Angiotensinogen 
Mechanical 
stretch 
SB202190, 
SB203580, 
DN-p38 
Rat [96,97] 
↓ ADAMTS1 IL-1 SB203580, 
BIRB-0796 
Human [59] 
Abbreviations: ADAMTS: a disintegrin and metalloproteinase domain with 
thrombospondin motifs; AGEs: advanced glycation end products; Ang II: 
angiotensin II; -AR: beta-adrenergic receptor; DN: dominant negative; ICAM: 
intercellular cell adhesion molecule; IL: interleukin; MCP: monocyte 
chemoattractant protein; MMP: matrix metalloproteinase; SDF: stromal-
derived factor; TIMP: tissue inhibitor of metalloproteinase; TGF: transforming 
growth factor; TNF: tumor necrosis factor; VCAM: vascular cell adhesion 
molecule. 
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Table 4. Effect of JNK inhibition on cardiac fibroblast function in vitro 
Target  Stimulus  Inhibitor CF Source Reference 
ECM turnover 
↑ MMP-3 IL-1 SP600125 Rat [90] 
↑ MMP-9 IL-1 SP600125 Rat [106] 
Cell function 
↑ Myofibroblast ET-1 SP600125 Rat [103] 
↑ Cell migration IL-1 SP600125 Rat [101] 
↑ Cell migration IL-18 SP600125 Rat [104] 
↑ Cell proliferation CXCL16 SP600125 Rat [105] 
Other 
↑ Periostin High glucose SP600125 Rat [108] 
↑ Osteopontin Ang II +  
IL-1/TNF 
SP600125 Rat [109] 
↑ PAI-1 Ang II, ET-1 DN-JNK Rat [110] 
Abbreviations: Ang II: angiotensin II; CXCL: CXC ligand; DN: dominant 
negative; ET: endothelin; IL: interleukin; MMP: matrix metalloproteinase; 
PAI: plasminogen activator inhibitor; TNF: tumor necrosis factor. 
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Environmental stress
Proinflammatory cytokines
Growth factors
MKK3, MKK4, MKK6
MAPK p38, p38, p38, p38
MAPKK
MAPKKK MEKK1-4, MLK3, TAK1, ASK1, 
DLK1, TAO1, TAO2, TPL2, ZAK1 
Transcription factors
ATF1/2/6, ELK1, CREB, 
MEF2A/C/D, p53, USF1, 
CHOP, SAP1, Max, NFAT, 
HBP-1, C/EBP
Other targets
MAPKAPK2/3, MSK1/2, 
MNK1/2, Tau, Bax,
PRAK, cyclin D1, PLA2, 
NHE1, keratin 8
Fig. 2. The p38 signaling pathway
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MKK4, MKK7
MAPK JNK1, JNK2, JNK3
MAPKK
MAPKKK
MEKK1-4, MLK1-4,
TAK1, ASK1 
Transcription factors
c-Jun, JunD, ATF2/3, 
ELK1, p53, SMAD4, 
NFAT4, HSF1, c-Myc, 
PPAR, GR, RXR 
Other targets
Bcl-2, Bcl-XL, Bad,
Bim, Bax, 14-3-3, IRS-1, 
AKT, JIP1/3, paxillin,
Tau, MAP2/1B
JIP
Fig. 3. The JNK signaling pathway
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